Skip to main content
VA Rating Assistant
Estimate

These guides are AI-generated educational summaries — not legal or medical advice.

C&P Exam Prep: Uterine Cancer (Malignant Neoplasm)

DC 7630 gynecological 38 CFR 4.116

DBQ Overview

Interview + Physical
Form Name
Gynecological_Conditions
Form Code
Gynecological_Conditions
Page Count
10
Examiner Type
Gynecologist, Gynecologic Oncologist, or appropriate clinician
Estimated Duration
30-45 minutes
Exam Format
Interview + Physical

What to Expect During Your Exam

Exam Overview

To evaluate the current severity, residuals, and functional impact of uterine cancer (malignant neoplasm of the uterus) for VA disability rating purposes under 38 CFR 4.116, Diagnostic Code 7630. The exam determines whether the cancer is active, in remission, or has resulted in residual conditions following treatment, and rates accordingly.

What the examiner evaluates:

  • Current diagnosis status: active malignancy vs. remission vs. residuals only
  • Cancer type (endometrial, sarcoma, other), stage, and grade at diagnosis
  • Whether primary or secondary/metastatic malignancy
  • Treatments received: surgery (hysterectomy, oophorectomy), radiation therapy, chemotherapy, immunotherapy, hormone therapy
  • Treatment completion dates and anticipated completion dates
  • Surgical residuals: removal of uterus, ovaries, fallopian tubes
  • Radiation therapy residuals: vaginal stenosis, urinary incontinence, bowel symptoms, lymphedema
  • Chemotherapy residuals: neuropathy, fatigue, anemia, immune suppression
  • Current gynecological symptoms: pelvic pain, abnormal bleeding, discharge, pelvic pressure
  • Urinary symptoms: incontinence severity, absorbent material use, fistulas
  • Bowel symptoms secondary to treatment
  • Anemia related to cancer or treatment
  • Presence of prolapse or pelvic floor dysfunction
  • Impact on daily activities, work, and quality of life
  • Recent imaging, labs (CBC including HGB/HCT), and oncology records
  • Frequency of ongoing oncology follow-up visits

Examination is typically conducted in a clinical setting with a gynecologist or gynecologic oncologist. A physical/pelvic examination may be performed. Bring all oncology records, surgical reports, pathology reports, imaging results, and a current medication list. If you have had radiation or chemotherapy, bring documentation of treatment dates and any recorded side effects. You have the right to request exam recording in most states.

Typical duration: 30-45 minutes

Hemoglobin (HGB) and Hematocrit (HCT)

Blood counts to assess anemia related to cancer, cancer treatment, or abnormal uterine bleeding. The DBQ specifically captures HGB and HCT values.

What to expect:

A blood draw or review of recent lab results. The examiner will document the most recent HGB and HCT values and the date of testing.

Key thresholds:

  • HGB < 7.1 g/dL or HCT < 21% — May support 100% rating under anemia criteria; significant functional impairment
  • HGB 7.1-10.0 g/dL or HCT 21-30% — Moderate anemia; supports higher rating levels
  • HGB > 10 g/dL or HCT > 30% — Mild or resolved anemia; lower rating impact from anemia alone

Tips:

  • Bring copies of your most recent CBC lab results, especially if drawn within the last 90 days
  • If you have had recent chemotherapy, labs may reflect treatment-related anemia - note the timing
  • Mention any symptoms of anemia: extreme fatigue, shortness of breath, dizziness, palpitations
  • If labs are from a private provider, ensure they are submitted to your VA file before the exam

Pain considerations: Anemia-related fatigue can significantly worsen pelvic pain perception and overall functional capacity. Accurately describe how fatigue from anemia limits your daily activities.

Urinary Incontinence Severity Assessment

Frequency and severity of urinary leakage, often a residual of pelvic radiation, radical hysterectomy, or fistula formation. Rated by how often absorbent material must be changed daily.

What to expect:

The examiner will ask detailed questions about urinary leakage frequency, pad usage, and whether you use an appliance. They will assess whether you have urethrovaginal fistulas or other structural causes.

Key thresholds:

  • Does not require absorbent material — Lower rating for incontinence component
  • Requires absorbent material changed less than 2 times per day — Moderate rating impact for incontinence
  • Requires absorbent material changed 2-4 times per day — Higher rating impact for incontinence
  • Requires absorbent material changed more than 4 times per day — Highest rating impact for incontinence component; may support 60%+ for this residual alone
  • Requires use of an appliance (catheter, urinary collection device) — Significant rating impact; document appliance type

Tips:

  • Keep a 2-week diary of pad changes before your exam to report accurate frequency
  • Note whether leakage is stress incontinence (coughing, sneezing), urge incontinence, or continuous
  • Describe the largest amount of leakage per episode and whether pads are fully saturated
  • If you use a catheter or other appliance, bring documentation and be prepared to describe it

Pain considerations: Urinary urgency and leakage episodes can cause significant pain, embarrassment, and limit ability to work or participate in social activities. Describe the full functional impact, not just the physical symptom.

Pelvic Examination and Residual Assessment

Physical assessment of surgical residuals, vaginal changes post-radiation, prolapse, fistulas, and any remaining gynecological structures.

What to expect:

A pelvic examination to assess the vaginal vault, presence of vaginal stenosis or atrophy from radiation, cystocele, rectocele, prolapse, or fistulas. The examiner will note which organs have been surgically removed.

Key thresholds:

  • Complete hysterectomy with bilateral salpingo-oophorectomy — Permanent surgical residuals; rated under DC 7617, 7619 if separately claimed
  • Vaginal stenosis from radiation — Rated as vaginal condition residual; impacts sexual function and may cause pain
  • Urethrovaginal or vesicovaginal fistula — Rated under fistula criteria; significant rating impact
  • Pelvic floor prolapse (cystocele, rectocele, enterocele) — Rated separately; may increase overall combined rating

Tips:

  • Inform the examiner of all surgical procedures, including dates and facilities
  • Describe any pain during intercourse (dyspareunia), vaginal dryness, or difficulty with pelvic exams since treatment
  • Report any bowel changes, rectal pressure, or difficulty with defecation related to treatment
  • Mention lymphedema of the lower extremities if present after lymph node dissection

Pain considerations: Pelvic pain at rest and with activity, vaginal discomfort, and radiation proctitis all contribute to functional impairment. Describe your worst-day pain level and its specific triggers.

Estimate

Rating Criteria Breakdown

100% Active malignancy (uterine cancer currently active and not i ...

Active malignancy (uterine cancer currently active and not in remission) OR while actively undergoing antineoplastic treatment (chemotherapy, radiation, immunotherapy, or hormonal therapy for cancer). A 100% rating is assigned from the date of diagnosis or onset of treatment and continues for 6 months following the date of the last treatment. After 6 months post-treatment, the rating is reduced based on residual disability.

Key Symptoms

  • Active cancer diagnosis confirmed by pathology or imaging
  • Currently receiving chemotherapy, radiation therapy, immunotherapy, or antineoplastic hormonal therapy
  • Metastatic or advanced-stage uterine cancer
  • Cancer not yet in remission
  • Severe systemic effects of active cancer: weight loss, fatigue, pain, functional decline

CFR: Under 38 CFR 4.116, Note (a), a 100% rating shall be assigned from the date of diagnosis or commencement of antineoplastic therapy, whichever is earlier. Six months after the last treatment, the rating is reviewed and reduced based on residual disability under the appropriate diagnostic code.

100% Post-treatment continued 100% rating: The 100% rating contin ...

Post-treatment continued 100% rating: The 100% rating continues for 6 months following completion of the last antineoplastic treatment. During this period, the veteran continues at 100% regardless of response to treatment. After this period, rating is determined by residual disability.

Key Symptoms

  • Treatment completed within the past 6 months
  • Ongoing severe residuals from chemotherapy or radiation
  • Severe fatigue, immune suppression, neuropathy post-treatment
  • Recovery from surgery still ongoing
  • Significant functional limitation from treatment effects

CFR: Per 38 CFR 4.116 Note (a): a 100% rating shall be continued for 6 months following the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedures. Following this period, the rating is based on the severity of residuals.

30% Post-treatment residual disability: After the 6-month period ...

Post-treatment residual disability: After the 6-month period following last treatment, rating is based on residual conditions. A 30% rating typically applies to moderate residuals such as pelvic pain requiring continuous treatment, moderate urinary symptoms, moderate vaginal symptoms, or ongoing need for regular oncology follow-up without active disease. Specific residuals are rated under their applicable diagnostic codes (e.g., DC 7617 for removal of uterus; DC 7619 for removal of ovary).

Key Symptoms

  • Cancer in remission with moderate residual symptoms
  • Moderate pelvic pain requiring continuous treatment
  • Urinary incontinence requiring absorbent material changed 2-4 times per day
  • Moderate vaginal stenosis from radiation
  • Moderate bowel symptoms from radiation proctitis
  • Regular oncology surveillance with no evidence of recurrence

CFR: After the mandatory 6-month 100% rating period following treatment completion, residuals of uterine cancer are rated under the most analogous gynecological diagnostic code. Pelvic pain, urinary symptoms, and surgical loss of organs are each rated separately and combined.

20% Mild to moderate residual disability post-treatment: Mild pe ...

Mild to moderate residual disability post-treatment: Mild pelvic pain, urinary symptoms not requiring frequent absorbent material changes, mild vaginal symptoms, or minimal treatment-related residuals. Applies when cancer is in confirmed remission and residuals are present but mild.

Key Symptoms

  • Mild pelvic pain manageable without continuous treatment
  • Urinary incontinence requiring absorbent material changed less than 2 times per day
  • Mild vaginal dryness or stenosis
  • Mild fatigue related to treatment history
  • Irregular menstruation or menopausal symptoms from oophorectomy

CFR: Residuals rated at mild-to-moderate level under applicable gynecological diagnostic codes following confirmed remission. Each residual condition must be individually evaluated and combined per 38 CFR 4.25.

0% Complete remission with no significant residuals. Cancer is ...

Complete remission with no significant residuals. Cancer is not active, all treatment is completed, and no residual symptoms or functional impairment attributable to the malignancy or its treatment are present. A 0% noncompensable rating may still establish service connection for future complications.

Key Symptoms

  • Complete remission confirmed by imaging and oncology
  • No ongoing treatment
  • No functional limitations from cancer history
  • No residual pain, urinary, or bowel symptoms

CFR: A 0% rating is assigned when the condition is in complete remission with no residual disability. However, maintaining service connection is important for future recurrence or late-onset residuals.

How to Describe Your Symptoms

Active Cancer / Treatment Status

How to describe:

State clearly whether you are currently receiving treatment, when your last treatment was, and what type. Use precise dates. Distinguish between chemotherapy, radiation, surgery, immunotherapy, and hormonal therapy. State whether your oncologist has declared remission and on what date.

Worst-day example:

“My last chemotherapy infusion was on [date]. I am still experiencing severe nausea, fatigue so debilitating I cannot get out of bed for days after each cycle, hair loss, and mouth sores. On my worst days following treatment, I am completely bedridden and require assistance with basic self-care.”

What the examiner listens for:

Clear timeline of diagnosis, treatment type, treatment dates, and current cancer status. The examiner needs to populate treatment completion dates and determine whether the 6-month 100% rating window applies.

Understatements to avoid:

Do not say 'I'm doing okay' or 'the treatment is going well' without also describing the side effects and functional limitations. Do not omit treatments that have been completed - all treatment history affects the rating period.

Pelvic Pain and Pressure

How to describe:

Describe the location, quality (sharp, dull, cramping, burning), severity on a 0-10 scale, and frequency. Distinguish between constant and intermittent pain. Note what makes it worse (activity, intercourse, bowel movements, prolonged sitting or standing) and what provides relief.

Worst-day example:

“On my worst days, I have a constant, severe pelvic pain rated 8-9 out of 10 that radiates to my lower back and inner thighs. I cannot sit for more than 15 minutes, cannot walk more than one block, and the pain wakes me from sleep multiple times per night. Even with prescription pain medication, the pain is not fully controlled.”

What the examiner listens for:

Severity classification (mild, moderate, severe), frequency, impact on function, and whether pain requires continuous treatment. These directly map to the pain severity checkboxes on the DBQ and support specific rating levels.

Understatements to avoid:

Do not minimize pain by saying 'I manage it' or 'it's not that bad.' Report your typical worst-day level, not only your best day. Do not omit pain that interrupts sleep, work, or daily activities.

Urinary Incontinence and Bladder Symptoms

How to describe:

Describe the type (stress, urge, overflow, or continuous), frequency of leakage episodes, and how many pads or absorbent materials you change per day. State the size of pads and whether they are completely soaked. Mention any use of catheters, condom catheters, or other devices.

Worst-day example:

“I experience urinary leakage every time I cough, sneeze, or stand up quickly, and I also have sudden urge incontinence that does not give me time to reach the bathroom. On an average day I change 4-5 fully saturated pads. On my worst days, I change 6 or more and have had accidents that soaked through my clothing in public, causing me to limit leaving my home.”

What the examiner listens for:

Specific number of absorbent material changes per day, whether an appliance is required, presence of fistulas, and impact on daily life. These directly determine which incontinence rating tier is checked on the DBQ.

Understatements to avoid:

Do not underreport pad changes. Many veterans say 'I use pads' without specifying frequency. Do not omit embarrassment, social isolation, or work limitations caused by incontinence.

Treatment Residuals (Radiation, Chemotherapy, Surgery)

How to describe:

For radiation: describe vaginal stenosis, dryness, pain with intercourse, bowel changes (diarrhea, urgency, rectal bleeding), bladder urgency, and lymphedema. For chemotherapy: describe neuropathy (numbness, tingling in hands/feet), persistent fatigue, cognitive effects ('chemo brain'), nausea, and immune suppression. For surgery: describe what was removed, when, and the resulting hormonal and functional changes.

Worst-day example:

“Since completing radiation, I have severe vaginal stenosis that makes gynecologic exams extremely painful and has eliminated any ability to have sexual intercourse. I experience daily rectal urgency and 3-4 episodes of loose stools. I have chronic lymphedema in both legs that causes swelling, pain, and difficulty walking more than half a block. My chemotherapy-related peripheral neuropathy causes burning pain and numbness in my feet that worsens at night and prevents me from sleeping.”

What the examiner listens for:

Specific residuals that can be separately rated, their severity, and functional impact. The examiner must document all residuals to ensure each is captured on the DBQ and potentially rated under separate diagnostic codes.

Understatements to avoid:

Do not assume treatment side effects are temporary or irrelevant. Residuals from radiation and chemotherapy can be permanent and are ratable. Do not fail to mention bowel or bladder changes even if you think they are 'normal' after cancer treatment.

Functional and Occupational Impact

How to describe:

Describe specifically how your condition limits work, household activities, caregiving, exercise, and social participation. Use concrete examples: how many hours you can work, what tasks you can no longer do, how often you miss work or appointments, and what accommodations you require.

Worst-day example:

“I have been unable to return to my previous job as a [occupation] because I cannot stand for more than 20 minutes, require frequent bathroom access, and experience unpredictable fatigue and pain flares that prevent reliable attendance. I have missed more than 30 days of work in the past year due to treatment, recovery, and ongoing symptoms. I require help with grocery shopping, housecleaning, and childcare on my worst days.”

What the examiner listens for:

Concrete functional limitations that support occupational impairment and overall severity. This information populates the functional impact section of the DBQ and supports TDIU claims if applicable.

Understatements to avoid:

Do not say 'I do what I can' without explaining what you cannot do. Do not omit job loss, reduced hours, or career changes caused by your condition. Underreporting occupational impact is one of the most common reasons veterans receive lower ratings than warranted.

Frequency of Medical Care and Ongoing Treatment

How to describe:

State how often you see your oncologist, gynecologist, or other specialists. Describe ongoing treatments (hormonal therapy, maintenance medications, physical therapy for lymphedema, pelvic floor therapy). Note whether you are seen at a VA clinic or private facility.

Worst-day example:

“I see my oncologist every 3 months for surveillance imaging and bloodwork. I take daily hormone therapy and weekly physical therapy for lymphedema. I also take daily medications for pain, bladder urgency, and neuropathy. These appointments and treatments consume 2-3 days per month and require someone to drive me.”

What the examiner listens for:

Whether the veteran is regularly seen at clinic, the intensity of ongoing treatment, and whether symptoms require continuous treatment. This helps establish severity and populates key DBQ fields about treatment status.

Understatements to avoid:

Do not omit any ongoing treatments, even if they seem routine. Hormone replacement therapy, surveillance imaging, and lymphedema management are all active treatments that support rating severity.

Common Mistakes to Avoid

Prep Checklist

0/22 complete

Before Your Exam

Day Of

During the Exam

After the Exam

Your Rights During a C&P Exam

  • You have the right to a thorough, accurate, and unbiased C&P examination conducted by a qualified examiner (gynecologist or gynecologic oncologist for this condition).
  • You have the right to request a copy of the completed DBQ examination report and to review it for accuracy before a rating decision is issued.
  • You have the right to record your C&P examination in most states. Check your state's consent laws before the exam and bring appropriate recording equipment if you choose to exercise this right.
  • You have the right to bring a support person, advocate, or VSO representative to your C&P examination.
  • You have the right to submit additional evidence, lay statements, and medical opinions at any point before a rating decision becomes final.
  • You have the right to request a new or supplemental examination if you believe the original examination was inadequate, incomplete, or inaccurate.
  • Under 38 CFR 4.116 and VA Note (a) for malignant neoplasms, you have the right to a 100% rating from the date of diagnosis or commencement of antineoplastic treatment, whichever is earlier, and for 6 months following the last treatment - regardless of response to treatment.
  • You have the right to the benefit of the doubt under 38 U.S.C. - 5107(b) when there is an approximate balance of positive and negative evidence regarding any issue material to your claim.
  • You have the right to claim each residual condition from cancer treatment (urinary incontinence, bowel symptoms, lymphedema, neuropathy, hormonal effects, surgical organ loss) as a separately ratable disability.
  • You have the right to claim Total Disability based on Individual Unemployability (TDIU) if your service-connected conditions, individually or in combination, prevent you from maintaining substantially gainful employment.
  • You have the right to a predetermination notice before any proposed rating reduction and the right to submit evidence or request a hearing to prevent the reduction.
  • You have the right to an IME (Independent Medical Examination) or nexus opinion from a private physician to supplement or counter VA examination findings.

Related Conditions

Get Personalized C&P Exam Preparation

Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.

Start Free Analysis Sign in for personalized prep

This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.